754 - Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32)

Presenting Author(s)

• 

  Johan A. Maertens, MD PhD

  Professor
  KU Leuven
  Leuven, Brussels Hoofdstedelijk Gewest, Belgium

  Disclosure: Disclosure(s): F2G Ltd: Advisor/Consultant (); Gilead Sciences Ltd: Advisor/Consultant (); Mundipharma: Advisor/Consultant (); Pfizer Inc: Advisor/Consultant ()

  Slides

Co-Author(s)

• 

  George R. Thompson, III, MD

  Professor
  University of California Davis Medical Center
  Sacramento, California, United States

  Disclosure: Disclosure(s): Amplyx: Advisor/Consultant (), Grant/Research Support (); Astellas: Advisor/Consultant (), Grant/Research Support (); Cidara: Advisor/Consultant (), Grant/Research Support (); F2G: Advisor/Consultant (), Grant/Research Support (); Merck: Grant/Research Support (); Pfizer: DSMB (); Scynexis: Advisor/Consultant (), Grant/Research Support ()
• 

  Andrej Spec, MD, MSCI

  Assistant Professor
  Washington University in St. Louis
  St. Louis, Missouri, United States

  Disclosure: Disclosure(s): Astellas: Grant/Research Support ()
• SH

  Sarah P. Hammond, MD

  Director of Hematology/Oncology Infectious Diseases
  Massachusetts General Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): F2G: Advisor/Consultant (), Grant/Research Support (); GSK: Grant/Research Support (); Merck: Grant/Research Support (); pfizer: Advisor/Consultant (); Scynexis: Grant/Research Support ()
• BR

  Bart Rijnders, MD, PhD

  Erasmus MC University Medical Center
  Rotterdam, Zuid-Holland, Netherlands

  Disclosure: Disclosure(s): F2G: Advisor/Consultant ()
• PW

  P. Lewis White, PhD

  University Hospital of Wales
  Cardiff, Wales, United Kingdom

  Disclosure: Disclosure(s): Associates of Cape Cod: Honoraria (); F2G: Advisor/Consultant (); Gilead: Grant/Research Support (); IMMY: Honoraria (); Pfizer: Advisor/Consultant (), Honoraria ()
• OC

  Oliver A. Cornely, Prof. Dr.

  Prof.
  University of Cologne, Faculty of Medicine and University Hospital Cologne
  Cologne, Nordrhein-Westfalen, Germany

  Disclosure: Disclosure(s): Abbott: Honoraria (); Abbvie: Advisor/Consultant (); Actelion: Board Member (); Al-Jazeera Pharmaceuticals: Honoraria (); Allecra Therapeutics: Board Member (); Amplyx: Advisor/Consultant (), Grant/Research Support (); Astellas: Honoraria (); Basilea: Advisor/Consultant (), Grant/Research Support (); Biocon: Advisor/Consultant (); Biosys: Advisor/Consultant (); BMBF: Grant/Research Support (); Cidara: Advisor/Consultant (), Board Member (), Expert Testimony (), Grant/Research Support (); CoRe Consulting: Stocks/Bonds (); Da Volterra: Advisor/Consultant (); DLR: Grant/Research Support (); DZIF: Grant/Research Support (); Entasis: Board Member (); EU Directorate-General for Resarch and Innovation: Grant/Research Support (); F2G: Grant/Research Support (); German Patent and Trade Mark Office: German patent (DE 10 2021 113 007.7) (); Gilead: Advisor/Consultant (), Grant/Research Support (); Grupo Biotoscana/United Medical/Knight: Honoraria (); Hikma: Honoraria (); IQVIA: Board Member (); Janssen: Board Member (); Matinas: Advisor/Consultant (), Grant/Research Support (); MedPace: Advisor/Consultant (), Grant/Research Support (); MedScape: Honoraria (); MedUpdate: Honoraria (); Menarini: Advisor/Consultant (); Merck/MSD: Grant/Research Support (), Honoraria (); Molecular Partners: Advisor/Consultant (); MSG-ERC: Advisor/Consultant (); Mundipharma: Grant/Research Support (); Mylan: Honoraria (); Noxxon: Advisor/Consultant (); Octapharma: Advisor/Consultant (), Grant/Research Support (); Paratek: Board Member (); Pardes: Advisor/Consultant (); Pfizer: Grant/Research Support (), Honoraria (); Projektträger Jülich: Grant/Research Support (); PSI: Advisor/Consultant (), Board Member (); Pulmocide: Board Member (); Scynexis: Advisor/Consultant (), Grant/Research Support (); Seres: Advisor/Consultant (); Shionogi: Board Member (); Wiley (Blackwell): Editor-in-Chief, Mycoses ()
• LF

  Lesley Fitton, BSc

  Senior Director
  F2G Ltd
  Manchester, England, United Kingdom

  Disclosure: Disclosure(s): F2G Ltd: Employee (), Stocks/Bonds ()
• AD

  Aaron Dane, MSc

  Director
  Danestat Consulting Limited
  Macclesfield, England, United Kingdom

  Disclosure: Disclosure(s): Amplyx: Advisor/Consultant (); AN2 therapeutics: Advisor/Consultant (); Artizan: Advisor/Consultant (); Cidara: Advisor/Consultant (); ContraFect: Advisor/Consultant (); Correvio: Advisor/Consultant (); Davolterra: Advisor/Consultant (); Destiny Pharma: Advisor/Consultant (); Entasis: Advisor/Consultant (); F2G Limited: Advisor/Consultant (); GSK: Advisor/Consultant (); Humanigen: Advisor/Consultant (); Kymab: Advisor/Consultant (); Modis: Advisor/Consultant (); Orca: Advisor/Consultant (); Pfizer: Advisor/Consultant (); Phico: Advisor/Consultant (); Pled Pharma: Advisor/Consultant (); Rare Thyroid: Advisor/Consultant (); Roche: Advisor/Consultant (); Scynexis: Advisor/Consultant (); Sinovent: Advisor/Consultant (); Spero Therapeutics: Advisor/Consultant (); Transcrip: Advisor/Consultant (); Venatorx: Advisor/Consultant ()
• 

  John H. Rex, MD

  Chief Medical Officer
  F2G, Limited
  WELLESLEY HILLS, MA, United States

  Disclosure: Disclosure(s): Advent Life Sciences: Operating Partner (), Ownership Interest (); AMR Action Fund: Advisor/Consultant (); AstraZeneca: Stocks/Bonds (); Basilea Pharmaceutica: Advisor/Consultant (); Bugworks Research, Inc.: Advisor/Consultant (); F2G, Limited: Employee (), Stocks/Bonds (); Forge Therapeutics: Advisor/Consultant (); GlaxoSmithKline: Advisor/Consultant (); Pfizer Pharmaceuticals: Honoraria (); Sumitovant: Advisor/Consultant ()
• SC

  Sharon C. Chen, PhD MBBS

  Professor
  Westmead Hospital
  Sydney, New South Wales, Australia

  Disclosure: Disclosure(s): F2G PTy Ltd: Grant/Research Support (); MSD Australia: Grant/Research Support ()